文献速递间质性肺疾病

TLR9抑制减轻肺纤维化转化模型中的纤维增殖反应

Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

该研究探讨Toll样受体9(TLR9)在特发性肺纤维化(IPF)中的作用,利用两个独立IPF队列、多种成纤维细胞培养平台、小鼠体内模型及人精密切割肺切片系统。结果显示血浆线粒体DNA激活TLR9与炎症因子表达及无移植生存期恶化相关,直接抑制TLR9可减轻纤维增殖反应。

要点

  • 血浆线粒体DNA激活TLR9与IPF患者炎症因子表达及无移植生存期恶化相关。
  • TLR9通过TGF-β1和硬基质介导成纤维细胞活化,直接抑制TLR9可改善此过程。
  • 直接TLR9抑制在体内和体外肺纤维化模型中减轻纤维增殖反应,具治疗潜力。

核心结论

  • 直接抑制TLR9可减轻临床前肺纤维化模型中的纤维增殖反应,显示治疗IPF及相关纤维化肺病的潜力。

研究设计与样本

  • 研究采用两个独立IPF患者队列、多种体外成纤维细胞培养平台、小鼠体内模型及人精密切割肺切片离体系统。

主要发现

  • 在两个独立IPF队列中,血浆线粒体DNA激活TLR9,与单核细胞趋化蛋白1、IL-6、肿瘤坏死因子-α及IFN-γ诱导蛋白10表达相关,并伴无移植生存期恶化。
  • 细胞培养平台显示TLR9通过转化生长因子-β1和硬基质介导成纤维细胞活化,其拮抗(尤其直接抑制)可改善该过程及上述药效学终点产生。
  • 在体内和离体肺纤维化模型中,直接TLR9抑制减轻纤维增殖反应。

临床怎么用

  • 直接TLR9拮抗可能成为IPF及相关纤维化肺病的潜在治疗策略,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease for which current treatment options only slow clinical progression. Previously, we identified a subset of patients with IPF with an accelerated disease course associated with fibroblast expression of Toll-like receptor 9 (TLR9) mediated by interactions with its ligand mitochondrial DNA. Objectives: We aimed to show that TLR9 activation induces fibroproliferative responses that are abrogated by its antagonism by using two commercially available indirect inhibitors and a proprietary, selective direct small-molecule inhibitor. Methods: We employed two independent cohorts of patients with IPF, multiple in vitro fibroblast cell culture platforms, an in vivo mouse model, and an ex vivo human precision-cut lung slices system to investigate the clinical and biologic significance of TLR9 in this disease. Measurements and Main Results: In two independent IPF cohorts, plasma mitochondrial DNA activates TLR9 in a manner associated with the expression of monocyte chemoattractant protein 1, IL-6, tumor necrosis factor-α, and IFN-γ-inducible protein 10 and worsened transplant-free survival. Our cell culture platform showed that TLR9 mediates fibroblast activation via transforming growth factor-β1 and stiff substrates and that its antagonism, particularly direct inhibition, ameliorates this process, including production of these TLR9-associated pharmacodynamic endpoints. We further demonstrated that direct TLR9 inhibition mitigates these fibroproliferative responses in our in vivo and ex vivo models of pulmonary fibrosis. Conclusions: In this novel study, we found that direct TLR9 inhibition mitigates fibroproliferative responses in preclinical models of pulmonary fibrosis. Our work demonstrates the therapeutic potential of direct TLR9 antagonism in IPF and related fibrotic lung diseases.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Trujillo G, Regueiro-Ren A, Liu C, et al. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025. PMID: 39189851. doi:10.1164/rccm.202401-0065OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。